

# Nicolaus KrÄƒger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/49851/publications.pdf>

Version: 2024-02-01

467  
papers

24,268  
citations

7096

78  
h-index

13379

130  
g-index

483  
all docs

483  
docs citations

483  
times ranked

15518  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. <i>Haematologica</i> , 2023, 108, 890-897.	3.5	65
2	Hematopoietic stem cell boost for persistent neutropenia after CAR-T-cell therapy: a GLA/DRST study. <i>Blood Advances</i> , 2023, 7, 555-559.	5.2	19
3	Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. <i>Haematologica</i> , 2022, 107, 857-867.	3.5	32
4	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. <i>Haematologica</i> , 2022, 107, 1054-1063.	3.5	20
5	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. <i>Haematologica</i> , 2022, 107, 1045-1053.	3.5	87
6	Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 183-190.	2.4	12
7	Iron Chelation With Deferasirox Increases Busulfan AUC During Conditioning Chemotherapy Prior to Allogeneic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 115.e1-115.e5.	1.2	3
8	Impact of donor-derived CD34+ infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 261-270.	2.4	9
9	Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis. <i>Bone Marrow Transplantation</i> , 2022, 57, 510-512.	2.4	6
10	Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis. <i>Blood Advances</i> , 2022, 6, 1222-1231.	5.2	20
11	Post-transplant MFC-MRD status on day +100 predicts outcomes for refractory AML patients. <i>Transplantation and Cellular Therapy</i> , 2022, , .	1.2	3
12	Population dynamics in colonizing vancomycin-resistant <i>Enterococcus faecium</i> isolated from immunosuppressed patients. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 28, 267-273.	2.2	5
13	Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). <i>Annals of Oncology</i> , 2022, 33, 259-275.	1.2	139
14	Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis. <i>Haematologica</i> , 2022, 107, 1840-1849.	3.5	56
15	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. <i>Bone Marrow Transplantation</i> , 2022, 57, 742-752.	2.4	45
16	Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 768-774.	2.4	8
17	High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 337.e1-337.e10.	1.2	13
18	Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. <i>Bone Marrow Transplantation</i> , 2022, 57, 896-902.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Comparison of single copy gene-based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19-directed CAR T cells in treated patients. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	5
20	Detection of human herpes virus 6 DNA and chromosomal integration after allogeneic hematopoietic stem cell transplantation: a retrospective single center analysis. <i>Transplant Infectious Disease</i> , 2022, , .	1.7	5
21	Immunotherapy in Myeloma: A Theme Issue in Honor of Prof. Dr. GÅrsta Gahrton. <i>Hemato</i> , 2022, 3, 1-2.	0.6	0
22	Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 374.e1-374.e9.	1.2	4
23	Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19. <i>Bone Marrow Transplantation</i> , 2022, 57, 1180-1182.	2.4	3
24	Improving allogeneic stem cell transplantation in myelofibrosis. <i>International Journal of Hematology</i> , 2022, 115, 619.	1.6	3
25	Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1072-1078.	2.4	4
26	Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1116-1123.	2.4	5
27	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. <i>Bone Marrow Transplantation</i> , 2022, 57, 1217-1239.	2.4	119
28	Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation. <i>Pharmaceutics</i> , 2022, 14, 1145.	4.5	1
29	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3541.	2.4	4
30	Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1548-1555.	2.4	3
31	Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2022, 57, 1556-1563.	2.4	8
32	Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1539-1547.	2.4	1
33	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021, 35, 215-224.	7.2	34
34	Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia. <i>Leukemia</i> , 2021, 35, 585-594.	7.2	18
35	Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 843-851.	7.0	25
36	Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 210-217.	2.4	7

#	ARTICLE	IF	CITATIONS
37	Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , 2021, 56, 605-613.	2.4	6
38	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 622-634.	2.4	9
39	Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia â€” a study of the Acute Leukemia Working Party of the EBMT. <i>Leukemia and Lymphoma</i> , 2021, 62, 399-409.	1.3	3
40	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021, 96, 69-79.	4.1	40
41	Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 95.e1-95.e4.	1.2	12
42	Role of preâ€”transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML. <i>European Journal of Haematology</i> , 2021, 106, 606-615.	2.2	12
43	Allogeneic stem cell transplant in patients with acute myeloid leukemia and Karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Cancer Medicine</i> , 2021, 10, 23-33.	2.8	7
44	The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review. <i>Annals of Hematology</i> , 2021, 100, 405-419.	1.8	4
45	Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study. <i>Bone Marrow Transplantation</i> , 2021, 56, 692-695.	2.4	3
46	1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 419-433.	2.4	8
47	Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2021, 56, 529-531.	2.4	1
48	Total body irradiation + fludarabine compared to busulfan + fludarabine as â€”reduced-toxicity conditioningâ€”for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 481-491.	2.4	10
49	Viral Dynamics of SARS-CoV-2 in Critically Ill Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients with COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 242-245.	5.6	12
50	Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection. <i>Bone Marrow Transplantation</i> , 2021, 56, 1478-1481.	2.4	9
51	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. <i>Bone Marrow Transplantation</i> , 2021, 56, 1651-1664.	2.4	221
52	Thiotepaâ€”busulfanâ€”fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1593-1602.	2.4	8
53	Conditioning intensity before allogeneic haematopoietic stem cell transplantation: a quality control audit. <i>British Journal of Haematology</i> , 2021, 192, e151-e154.	2.5	3
54	Expert review on softâ€”tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.5	67

#	ARTICLE	IF	CITATIONS
55	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	1.2	6
56	Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend when and for whom in 2021?. <i>Haematologica</i> , 2021, 106, 1794-1804.	3.5	36
57	TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 630429.	4.8	19
58	A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. <i>Blood Advances</i> , 2021, 5, 1760-1769.	5.2	22
59	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1944-1952.	2.4	7
60	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 592-601.	2.5	17
61	Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 2160-2172.	2.4	25
62	Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. <i>American Journal of Hematology</i> , 2021, 96, E207-E210.	4.1	2
63	Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect. <i>Hemato</i> , 2021, 2, 207-216.	0.6	1
64	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica</i> , 2021, 106, 2054-2065.	3.5	27
65	IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 686-693.	0.4	2
66	aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1269-1278.	3.7	16
67	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2021, 14, 84.	17.0	27
68	Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. <i>Leukemia</i> , 2021, 35, 3551-3560.	7.2	40
69	Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020. <i>Journal of Clinical Medicine</i> , 2021, 10, 2274.	2.4	19
70	Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 2367-2381.	2.4	1
71	COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. <i>Leukemia</i> , 2021, 35, 2885-2894.	7.2	153
72	Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting. <i>Blood Advances</i> , 2021, 5, 2523-2527.	5.2	19

#	ARTICLE	IF	CITATIONS
73	Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. <i>Bone Marrow Transplantation</i> , 2021, 56, 2079-2087.	2.4	37
74	Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of <scp>EBMT</scp> and the Spanish Myelofibrosis Registry. <i>American Journal of Hematology</i> , 2021, 96, 1186-1194.	4.1	17
75	Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). <i>Journal of Clinical Oncology</i> , 2021, 39, 3318-3327.	1.6	44
76	Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study. <i>Bone Marrow Transplantation</i> , 2021, 56, 2820-2825.	2.4	7
77	Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2742-2748.	2.4	5
78	Predictive factors for outcome of first allogeneic transplant for elderly patients with acute lymphoblastic leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 831-840.	0.4	1
79	Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML. <i>Bone Marrow Transplantation</i> , 2021, 56, 2834-2841.	2.4	12
80	Visions for a JACIE Quality Management System 4.0. <i>Bone Marrow Transplantation</i> , 2021, 56, 2876-2881.	2.4	3
81	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reducedâ€­intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. <i>British Journal of Haematology</i> , 2021, 195, 417-428.	2.5	9
82	Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 999.e1-999.e10.	1.2	6
83	Enhanced Immune Reconstitution of Î³Î´ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 841-850.	1.2	13
84	Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 3084-3087.	2.4	2
85	Evaluation of the Robustness of Therapeutic Drug Monitoring Coupled with Bayesian Forecasting of Busulfan with Regard to Inaccurate Documentation. <i>Pharmaceutical Research</i> , 2021, 38, 1721-1729.	3.5	3
86	Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101332.	1.7	3
87	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Leukemia</i> , 2021, 35, 3585-3588.	7.2	72
88	Anti-Thymocyte Globulin Treatment Augments 1,25-Dihydroxyvitamin D3 Serum Levels in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 803726.	4.8	3
89	HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 771449.	4.8	11
90	Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. <i>Bone Marrow Transplantation</i> , 2020, 55, 356-366.	2.4	12

#	ARTICLE	IF	CITATIONS
91	Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 595-602.	2.4	17
92	Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allograft: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 451-457.	2.0	25
93	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. <i>Leukemia</i> , 2020, 34, 283-292.	7.2	48
94	In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. <i>Leukemia</i> , 2020, 34, 317-321.	7.2	34
95	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	2.4	196
96	Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 188, 428-437.	2.5	12
97	Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 1050-1058.	2.4	42
98	Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP. <i>European Journal of Haematology</i> , 2020, 104, 181-189.	2.2	7
99	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 884-890.	2.4	13
100	Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1642-1646.	2.4	4
101	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	3.5	230
102	B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis. <i>European Journal of Haematology</i> , 2020, 104, 318-327.	2.2	41
103	Incidence and Outcome of Late Relapse after Allogeneic Stem Cell Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2279-2284.	2.0	4
104	Double Counting of Patients in Meta-analyses of Observational Studies—Reply. <i>JAMA Oncology</i> , 2020, 6, 787.	7.1	0
105	Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i> Internal Tandem Duplication Mutation (SORMAIN). <i>Journal of Clinical Oncology</i> , 2020, 38, 2993-3002.	1.6	335
106	Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR. <i>Cancers</i> , 2020, 12, 1970.	3.7	23
107	Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2047-2052.	2.0	6
108	Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT. <i>Frontiers in Immunology</i> , 2020, 11, 1537.	4.8	2

#	ARTICLE	IF	CITATIONS
109	Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. <i>Blood</i> , 2020, 136, 2051-2064.	1.4	56
110	FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2165-2173.	2.0	17
111	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
112	Preventing Graft-Versus-Host Disease Without Losing Graft-Versus-Leukemia Effect After Allogeneic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2020, 38, 3357-3360.	1.6	5
113	Major central nervous system complications after allogeneic stem cell transplantation: A large retrospective study on 888 consecutive adult patients. <i>European Journal of Haematology</i> , 2020, 105, 722-730.	2.2	5
114	Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression. <i>Bone Marrow Transplantation</i> , 2020, 55, 1817-1820.	2.4	1
115	Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2020, 26, 5879-5886.	7.0	3
116	Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis. <i>Cancers</i> , 2020, 12, 3098.	3.7	10
117	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	17
118	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. <i>Bone Marrow Transplantation</i> , 2020, 55, 2071-2076.	2.4	163
119	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
120	Monocenter study on epidemiology, outcomes, and risk factors of infections in recipients of 166 allogeneic stem cell transplantations during 1Åyear. <i>European Journal of Haematology</i> , 2020, 105, 126-137.	2.2	7
121	Development of CAR-T cell therapies for multiple myeloma. <i>Leukemia</i> , 2020, 34, 2317-2332.	7.2	68
122	Cytogenetic risk score maintains its prognostic significance in <scp>AML</scp> patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1135-1141.	4.1	6
123	Clonal Evolution after Allogeneic Hematopoietic Stem Cell Transplantation: The Case of Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e167-e170.	2.0	0
124	Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. <i>Theranostics</i> , 2020, 10, 2645-2658.	10.0	17
125	Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 190, 437-441.	2.5	4
126	Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs). <i>Cells</i> , 2020, 9, 321.	4.1	46



#	ARTICLE	IF	CITATIONS
127	Selecting patients with primary myelofibrosis for stem cell transplant using clinical, mutational, and transplant-specific profiles. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e80.	0.9	0
128	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Ts come into focus. <i>Bone Marrow Transplantation</i> , 2020, 55, 1604-1613.	2.4	147
129	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	4.6	319
130	Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 172-178.	4.1	46
131	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. <i>Bone Marrow Transplantation</i> , 2020, 55, 1093-1102.	2.4	78
132	Implementation analysis of patient reported outcomes (PROs) in oncological routine care: an observational study protocol. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 3.	2.4	11
133	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020, 34, 1898-1906.	7.2	16
134	Fear of disease progression and relevant correlates in acute leukemia patients prior to allogeneic hematopoietic stem cell transplantation. <i>Psycho-Oncology</i> , 2020, 29, 1248-1254.	2.3	9
135	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group. <i>American Journal of Hematology</i> , 2020, 95, 809-816.	4.1	30
136	Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression with cyclosporine A. <i>Haematologica</i> , 2020, 105, 322-324.	3.5	14
137	Treosulfan conditioning for allogeneic transplantation in multiple myeloma – improved overall survival in first line haematopoietic stem cell transplantation – a large retrospective study by the Chronic Malignancies Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 189, e213-e217.	2.5	10
138	Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin. <i>Haematologica</i> , 2020, 105, 1138-1146.	3.5	19
139	Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 584520.	4.8	11
140	The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis. <i>Frontiers in Immunology</i> , 2020, 11, 614976.	4.8	10
141	Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2020, 11, 613954.	4.8	3
142	Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey. <i>Bone Marrow Transplantation</i> , 2020, 55, 2335-2338.	2.4	3
143	Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level. <i>Bone Marrow Transplantation</i> , 2020, 55, 2286-2293.	2.4	22
144	How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. <i>Blood Advances</i> , 2020, 4, 6283-6290.	5.2	89

#	ARTICLE	IF	CITATIONS
145	Development of a Short Instrument for Measuring Health-Related Quality of Life in Oncological Patients for Clinical Use: Protocol for an Observational Study. <i>JMIR Research Protocols</i> , 2020, 9, e17854.	1.0	2
146	ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF. <i>Leukemia</i> , 2019, 33, 99-109.	7.2	19
147	Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. <i>Bone Marrow Transplantation</i> , 2019, 54, 497-507.	2.4	11
148	Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. <i>Bone Marrow Transplantation</i> , 2019, 54, 17-25.	2.4	4
149	Prevention and treatment of relapse after stem cell transplantation by cellular therapies. <i>Bone Marrow Transplantation</i> , 2019, 54, 26-34.	2.4	14
150	Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. <i>Bone Marrow Transplantation</i> , 2019, 54, 402-417.	2.4	31
151	Methods and role of minimal residual disease after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 681-690.	2.4	7
152	Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. <i>Bone Marrow Transplantation</i> , 2019, 54, 44-52.	2.4	59
153	Allogeneic stem cell transplantation for myelofibrosis patients aged $\geq 65$ years. <i>European Journal of Haematology</i> , 2019, 103, 370-378.	2.2	11
154	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2008-2016.	2.0	20
155	Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2134-2142.	2.0	52
156	Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2267-2273.	2.0	7
157	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2167-2171.	2.0	69
158	Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects. <i>Drugs</i> , 2019, 79, 1499-1509.	10.9	24
159	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2060-2071.	2.4	6
160	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. <i>Blood</i> , 2019, 134, 892-899.	1.4	110
161	Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers. <i>JAMA Oncology</i> , 2019, 5, 1739.	7.1	76
162	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , 2019, 6, e573-e584.	4.6	140

#	ARTICLE	IF	CITATIONS
163	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 108.	17.0	51
164	Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation. <i>European Journal of Haematology</i> , 2019, 103, 552-557.	2.2	12
165	Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2823-2834.	2.5	7
166	JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. <i>Blood</i> , 2019, 134, 1832-1846.	1.4	42
167	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. <i>Haematologica</i> , 2019, 104, 929-936.	3.5	23
168	Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis. <i>Haematologica</i> , 2019, 104, 1230-1236.	3.5	12
169	EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). <i>Bone Marrow Transplantation</i> , 2019, 54, 1391-1398.	2.4	22
170	GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. <i>Lancet Haematology</i> , 2019, 6, e89-e99.	4.6	47
171	Induction, Bridging, or Straight Ahead: The Ongoing Dilemma of Allografting in Advanced Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e247-e249.	2.0	16
172	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1975-1983.	2.0	61
173	Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2013-2019.	2.4	21
174	Reduced intensity allogeneic stem cell transplantation for younger patients with myelofibrosis. <i>British Journal of Haematology</i> , 2019, 186, 484-489.	2.5	6
175	Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 689-697.	2.8	8
176	The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. <i>Annals of Hematology</i> , 2019, 98, 1755-1763.	1.8	35
177	Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Journal of Hematology and Oncology</i> , 2019, 12, 44.	17.0	26
178	A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 2404-2414.	1.3	15
179	The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1662-1667.	2.4	22
180	Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 725-732.	2.5	17

#	ARTICLE	IF	CITATIONS
181	State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. <i>Haematologica</i> , 2019, 104, 659-668.	3.5	56
182	Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. <i>Blood Cancer Journal</i> , 2019, 9, 46.	6.2	18
183	Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. <i>Haematologica</i> , 2019, 104, 2274-2282.	3.5	27
184	Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e204-e208.	2.0	23
185	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	2.4	218
186	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. <i>Bone Marrow Transplantation</i> , 2019, 54, 1575-1585.	2.4	129
187	Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Haematologica</i> , 2019, 104, 1782-1788.	3.5	48
188	Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. <i>Blood</i> , 2019, 133, 2233-2242.	1.4	121
189	Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2019, 54, 1625-1631.	2.4	11
190	Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e213-e220.	0.4	9
191	Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries. <i>Bone Marrow Transplantation</i> , 2019, 54, 1179-1188.	2.4	51
192	DAMIAN: an open source bioinformatics tool for fast, systematic and cohort based analysis of microorganisms in diagnostic samples. <i>Scientific Reports</i> , 2019, 9, 16841.	3.3	18
193	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. <i>Blood Cancer Journal</i> , 2019, 9, 88.	6.2	39
194	Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT). <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 370-375.	1.6	8
195	Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50 Years or Older with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 488-495.	2.0	21
196	HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 114-120.	2.0	27
197	Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 686-695.	7.2	24
198	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 522-528.	2.0	48

#	ARTICLE	IF	CITATIONS
199	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e128-e140.	2.0	40
200	Haploidentical <i>versus</i> unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2019, 104, 524-532.	3.5	68
201	Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an <i>ALWP/EBMT</i> analysis. <i>Journal of Internal Medicine</i> , 2019, 285, 407-418.	6.0	35
202	Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 335-342.	2.0	20
203	One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT). <i>Blood</i> , 2019, 134, 2035-2035.	1.4	36
204	TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes. <i>Blood</i> , 2019, 134, 3007-3007.	1.4	1
205	Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2019, 134, 2038-2038.	1.4	1
206	Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2019, 134, 324-324.	1.4	2
207	Myeloproliferative Neoplasms. , 2019, , 569-578.		1
208	Prevention and Treatment of Relapse by Drugs. , 2019, , 437-442.		1
209	Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2019, 134, 3327-3327.	1.4	0
210	Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis: a Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019, 134, 3338-3338.	1.4	0
211	Association of Donor-Recipient HLA Matching with Outcome of Unrelated Donor Hematopoietic Stem Cell Transplantation: A Study from the Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2019, 134, 3281-3281.	1.4	0
212	Oncogenic JAK2 <sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	166
213	Epidemiology and biology of relapse after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1379-1389.	2.4	85
214	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 683-691.	2.4	13
215	Improving Lentiviral Transduction of CD34 <sup>+</sup> Hematopoietic Stem and Progenitor Cells. <i>Human Gene Therapy Methods</i> , 2018, 29, 104-113.	2.1	27
216	Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 930-936.	2.0	11

#	ARTICLE	IF	CITATIONS
217	Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1372-1378.	2.0	20
218	Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2018, 53, 617-624.	2.4	45
219	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	30.7	216
220	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 255-263.	2.4	14
221	Melphalan 140 mg/m <sup>2</sup> or 200 mg/m <sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. <i>Haematologica</i> , 2018, 103, 514-521.	3.5	70
222	Acute hepatitis as a prequel to very severe aplastic anemia. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 51-54.	0.5	4
223	Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1-2.	2.4	6
224	Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2018, 11, 55.	17.0	51
225	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1548-1552.	2.4	6
226	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2018, 53, 1139-1148.	2.4	117
227	Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?. <i>Blood</i> , 2018, 131, 1989-1992.	1.4	43
228	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	1.4	140
229	Transplant results in adults with Fanconi anaemia. <i>British Journal of Haematology</i> , 2018, 180, 100-109.	2.5	25
230	What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?. <i>Journal of Internal Medicine</i> , 2018, 283, 166-177.	6.0	10
231	Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 276-281.	2.0	16
232	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	3.5	110
233	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 507-513.	2.0	10
234	Return to Work in Patients with Hematological Cancers 1 Year after Treatment: A Prospective Longitudinal Study. <i>Oncology Research and Treatment</i> , 2018, 41, 697-701.	1.2	11

#	ARTICLE	IF	CITATIONS
235	The science of evidence synthesis in hematopoietic stem-cell transplantation: Meta-analysis and quality assessment. <i>Advances in Cell and Gene Therapy</i> , 2018, 1, e12.	0.9	0
236	Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2152-2156.	2.0	65
237	Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2101-2109.	2.0	32
238	Prevention and treatment of relapse after stem cell transplantation with immunotherapy. <i>Bone Marrow Transplantation</i> , 2018, 53, 664-672.	2.4	11
239	Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. <i>European Journal of Haematology</i> , 2018, 101, 305-317.	2.2	39
240	Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2558-2567.	2.0	43
241	Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1399-1405.	2.0	24
242	Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of <sc>EBMT</sc>. <i>British Journal of Haematology</i> , 2018, 182, 418-422.	2.5	28
243	Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects. <i>Haematologica</i> , 2018, 103, 1527-1534.	3.5	5
244	Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 552-560.	2.4	35
245	Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. <i>Leukemia</i> , 2017, 31, 2161-2171.	7.2	145
246	Investigating the temporal course, relevance and risk factors of fatigue over 5 years: a prospective study among patients receiving allogeneic HSCT. <i>Bone Marrow Transplantation</i> , 2017, 52, 753-758.	2.4	21
247	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	1.4	278
248	Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 1361-1372.	1.8	49
249	Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. <i>Haematologica</i> , 2017, 102, e368-e370.	3.5	48
250	Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 667-675.e2.	0.4	12
251	Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with <sc>CLL</sc>: a retrospective analysis from the European Society for Blood and Marrow Transplantation (<sc>EBMT</sc>). <i>British Journal of Haematology</i> , 2017, 178, 521-533.	2.5	26
252	Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1095-1101.	2.0	89

#	ARTICLE	IF	CITATIONS
253	Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2017, 52, 811-817.	2.4	310
254	Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2017, 52, 1107-1112.	2.4	19
255	CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 405-411.	2.0	11
256	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 372-380.	2.4	53
257	Depression and anxiety following hematopoietic stem cell transplantation: a prospective population-based study in Germany. <i>Bone Marrow Transplantation</i> , 2017, 52, 1651-1657.	2.4	42
258	Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , 2017, 52, 1519-1525.	2.4	19
259	Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2184-2191.	2.0	28
260	Impact of molecular residual disease post allografting in myelofibrosis patients. <i>Bone Marrow Transplantation</i> , 2017, 52, 1526-1529.	2.4	42
261	Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). <i>Leukemia</i> , 2017, 31, 2523-2525.	7.2	71
262	Stability and Priority of Symptoms and Symptom Clusters Among Allogeneic HSCT Patients Within a 5-Year Longitudinal Study. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 493-500.	1.2	24
263	Jon van Rood (1926â€“2017). <i>Bone Marrow Transplantation</i> , 2017, 52, 1587-1587.	2.4	1
264	CAR-T cells: the narrow path between hope and bankruptcy?. <i>Bone Marrow Transplantation</i> , 2017, 52, 1588-1589.	2.4	24
265	In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review. <i>Bone Marrow Transplantation</i> , 2017, 52, 1233-1240.	2.4	7
266	Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes. <i>Seminars in Hematology</i> , 2017, 54, 154-158.	3.4	7
267	Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017, 10, 130.	17.0	38
268	Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT). <i>Annals of Hematology</i> , 2017, 96, 1379-1388.	1.8	17
269	Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study. <i>Journal of Cancer Survivorship</i> , 2017, 11, 203-210.	2.9	25
270	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 278-284.	2.0	38



#	ARTICLE	IF	CITATIONS
271	Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2017, 52, 191-196.	2.4	27
272	Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 209-215.	2.4	37
273	Cancer treatment-specific distress and its impact on posttraumatic stress in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). <i>Psycho-Oncology</i> , 2017, 26, 1164-1171.	2.3	26
274	Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 44-52.	2.0	49
275	The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis. <i>Bone Marrow Transplantation</i> , 2017, 52, 357-362.	2.4	13
276	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	5.0	166
277	Haploidentical transplant in patients with myelodysplastic syndrome. <i>Blood Advances</i> , 2017, 1, 1876-1883.	5.2	28
278	Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection. <i>Frontiers in Immunology</i> , 2017, 8, 41.	4.8	32
279	Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle. <i>Frontiers in Oncology</i> , 2017, 7, 287.	2.8	12
280	Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2017, 17, 839-845.	1.6	11
281	Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). <i>Journal of Clinical Oncology</i> , 2017, 35, 2157-2164.	1.6	183
282	Digital PCR Panel for Sensitive Hematopoietic Chimerism Quantification after Allogeneic Stem Cell Transplantation. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1515.	4.1	25
283	Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. <i>Journal of Hematology and Oncology</i> , 2016, 9, 89.	17.0	35
284	Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1615-1620.	2.0	46
285	Outcome Improvement After Allogeneic Stem-Cell Transplantation in Myelofibrosis. <i>Journal of Oncology Practice</i> , 2016, 12, 629-631.	2.5	7
286	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016, 101, 773-780.	3.5	35
287	The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years: a report from the EBMT acute leukemia working party. <i>Journal of Hematology and Oncology</i> , 2016, 9, 65.	17.0	17
288	Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1206-1211.	2.0	70

#	ARTICLE	IF	CITATIONS
289	Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2016, 51, 1391-1393.	2.4	9
290	Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 2212-2220.	1.6	41
291	Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2016, 51, 1223-1227.	2.4	60
292	Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. <i>Leukemia</i> , 2016, 30, 2047-2054.	7.2	59
293	Suspected encephalitis with <i>Candida tropicalis</i> and <i>Fusarium</i> detected by unbiased RNA sequencing. <i>Annals of Hematology</i> , 2016, 95, 1919-1921.	1.8	14
294	Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT. <i>Annals of Hematology</i> , 2016, 95, 1971-1978.	1.8	18
295	Correlation of somatic mutations with outcome after FLAMSA+busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2016, 97, 288-296.	2.2	14
296	Serial <sup>18</sup> F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1556-1559.	5.0	8
297	Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 872-873.	2.4	15
298	Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. <i>Bone Marrow Transplantation</i> , 2016, 51, 654-662.	2.4	9
299	Hematopoietic stem cell transplantation in Europe 2014: more than 40,000 transplants annually. <i>Bone Marrow Transplantation</i> , 2016, 51, 786-792.	2.4	338
300	Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 644-650.	2.0	10
301	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2016, 374, 43-53.	27.0	436
302	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.3	7
303	Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 89-95.	2.4	30
304	Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. <i>Leukemia</i> , 2016, 30, 562-569.	7.2	42
305	Ruxolitinib during Peritransplant Period for Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplantation Reduces Acute Graft-Versus-Host Disease. <i>Blood</i> , 2016, 128, 2242-2242.	1.4	5
306	Impact of Donor-Recipient Histocompatibility and CMV-Mismatch on Outcome of Allogeneic Stem Cell Transplantation for AML and MDS: A Retrospective Registry Study of the German Stem Cell Transplant Registry (DRST) of the German Working Group for Blood and Marrow Transplantation (DAG-KBT). <i>Blood</i> , 2016, 128, 2304-2304.	1.4	1

#	ARTICLE	IF	CITATIONS
307	Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT. <i>Blood</i> , 2016, 128, 4657-4657.	1.4	7
308	Salvage Use of Ibrutinib after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for B Cell Malignancies: A Study of the French Cooperative Group for CLL, the French Society for Blood and Marrow Transplantation (SFGM-TC), and the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancy and Lymphoma Working Parties. <i>Blood</i> , 2016, 128, 4659-4659.	1.4	8
309	Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2016, 128, 993-993.	1.4	9
310	Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins. <i>Oncotarget</i> , 2016, 7, 67061-67070.	1.8	0
311	Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 4663-4663.	1.4	0
312	Use of First or Second Generation TKI for CML after Allogeneic Stem Cell Transplantation: a Study By the CMWP of the EBMT. <i>Blood</i> , 2016, 128, 4685-4685.	1.4	2
313	CD133 marks a stem cell population that drives human primary myelofibrosis. <i>Haematologica</i> , 2015, 100, 768-779.	3.5	13
314	Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. <i>EBioMedicine</i> , 2015, 2, 2101-2109.	6.1	36
315	Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma. <i>Journal of Translational Medicine</i> , 2015, 13, 197.	4.4	6
316	Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. <i>British Journal of Haematology</i> , 2015, 171, 453-462.	2.5	27
317	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2015, 171, 239-246.	2.5	80
318	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e122-e124.	3.5	20
319	Possible Role of Minor H Antigens in the Persistence of Donor Chimerism after Stem Cell Transplantation; Relevance for Sustained Leukemia Remission. <i>PLoS ONE</i> , 2015, 10, e0119595.	2.5	11
320	Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. <i>Bone Marrow Transplantation</i> , 2015, 50, 1037-1056.	2.4	283
321	Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. <i>Blood</i> , 2015, 125, 3347-3350.	1.4	152
322	Current Challenges in Stem Cell Transplantation in Myelofibrosis. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 344-350.	2.3	13
323	Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. <i>Bone Marrow Transplantation</i> , 2015, 50, 476-482.	2.4	173
324	Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 489-495.	2.0	53

#	ARTICLE	IF	CITATIONS
325	Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusionsâ€”A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 653-660.	2.0	163
326	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. <i>Bone Marrow Transplantation</i> , 2015, 50, 505-510.	2.4	16
327	Impact of the revised international Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2015, 100, 100-100.	3.5	50
328	Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3144-3151.	1.6	119
329	Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. <i>Leukemia</i> , 2015, 29, 2062-2068.	7.2	455
330	Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societ� Fran�saise de Greffe de Moelle et Therapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1515-1523.	2.0	11
331	Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 392-399.	3.5	139
332	Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation. <i>Experimental Hematology</i> , 2015, 43, 462-468.e1.	0.4	59
333	Comparison of upfront tandem autologousâ€“allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2015, 50, 802-807.	2.4	13
334	JAK1/2 inhibition impairs T cell function <i>in vitro</i> and in patients with myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2015, 169, 824-833.	2.5	136
335	Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL). <i>Bone Marrow Transplantation</i> , 2015, 50, 1503-1507.	2.4	10
336	Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. <i>Blood Cancer Journal</i> , 2015, 5, e285-e285.	6.2	82
337	Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. <i>Bone Marrow Transplantation</i> , 2015, 50, 1542-1550.	2.4	80
338	Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1230-1236.	2.0	35
339	Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. <i>Bone Marrow Transplantation</i> , 2015, 50, 209-215.	2.4	108
340	Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. <i>Leukemia</i> , 2015, 29, 696-704.	7.2	36
341	Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1151-1162.	4.2	17
342	Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 744-750.	2.4	145

#	ARTICLE	IF	CITATIONS
343	JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. <i>Leukemia</i> , 2014, 28, 1736-1738.	7.2	90
344	Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients. <i>Blood Cancer Journal</i> , 2014, 4, e212-e212.	6.2	7
345	Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 126-130.	2.4	34
346	5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity. <i>Mediators of Inflammation</i> , 2014, 2014, 1-12.	3.0	37
347	Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. <i>Leukemia</i> , 2014, 28, 2235-2240.	7.2	93
348	Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantation intergroup study. <i>American Journal of Hematology</i> , 2014, 89, 174-180.	4.1	10
349	Allogeneic Stem Cell Transplant vs. Janus Kinase Inhibition in the Treatment of Primary Myelofibrosis or Myelofibrosis After Essential Thrombocythemia or Polycythemia Vera. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S36-S41.	0.4	6
350	Should Patients With High-Risk or Transformed Myelodysplastic Syndrome Proceed Directly to Allogeneic Transplant Without Prior Cytoreduction by Remission-Induction Chemotherapy or Hypomethylating Agent Therapy?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S42-S45.	0.4	6
351	Immune-Modulating Drugs and Hypomethylating Agents to Prevent or Treat Relapse after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 168-172.	2.0	7
352	Prophylaxis and treatment of GVHD: EBMT ELN working group recommendations for a standardized practice. <i>Bone Marrow Transplantation</i> , 2014, 49, 168-173.	2.4	252
353	Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , 2014, 28, 1552-1555.	7.2	56
354	Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 865-872.	2.4	151
355	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. <i>Leukemia</i> , 2014, 28, 993-1000.	7.2	92
356	Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8595-8600.	7.1	35
357	Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2014, 49, 1217-1222.	2.4	70
358	Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1841-1846.	2.0	53
359	CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 382-386.	2.0	74
360	Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 279-281.	2.0	83

#	ARTICLE	IF	CITATIONS
361	Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1274-1281.	2.0	18
362	Dynamic of Bone Marrow Fibrosis Regression Predicts Survival after Allogeneic Stem Cell Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 812-815.	2.0	46
363	Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 916-921.	3.5	62
364	Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. <i>Haematologica</i> , 2014, 99, 1582-1590.	3.5	36
365	Allogeneic Stem Cell Transplantation for CML in Accelerate or Blastic Phase. <i>Blood</i> , 2014, 124, 1220-1220.	1.4	1
366	Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers. <i>Blood</i> , 2014, 124, 2554-2554.	1.4	7
367	Long-Term Follow-up Data Support the Curative Potential of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2014, 124, 2561-2561.	1.4	3
368	Prognostic Impact of Splicing Factor Mutations in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 3171-3171.	1.4	1
369	Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial). <i>Blood</i> , 2014, 124, 320-320.	1.4	5
370	Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopoietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy). <i>Blood</i> , 2014, 124, 37-37.	1.4	9
371	Casein Kinase 1A1 (CSNK1A1) Is Recurrently Mutated in MDS Patients with Deletion of Chromosome 5q. <i>Blood</i> , 2014, 124, 4643-4643.	1.4	1
372	Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients. <i>Blood</i> , 2014, 124, 633-633.	1.4	0
373	EZH2 Mutations Are Drivers of Clonal Hematopoiesis and Leukemic Transformation in a Mouse Model of Primary Myelofibrosis. <i>Blood</i> , 2014, 124, 3211-3211.	1.4	1
374	Haploidentical Second Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Acute Leukemia Relapse after First Allo-HSCT: A Retrospective Registry Analysis of 60 Patients on Behalf of the German Cooperative Transplant Group. <i>Blood</i> , 2014, 124, 2590-2590.	1.4	1
375	Allogeneic HCT in Patients with 17p-CLL: Results of a Non-Interventional Study of the EBMT & Eric. <i>Blood</i> , 2014, 124, 1224-1224.	1.4	0
376	Allogeneic Stem Cell Transplantation after Conditioning with Treosulfan, Etoposide and Cyclophosphamide for Patients with Acute Lymphoblastic Leukemia (ALL) Not Eligible for TBI-Containing Regimens: A Phase II-Study on Behalf of the German ALL Study Group (GMALL) and the German Cooperative Transplant Study Group. <i>Blood</i> , 2014, 124, 2461-2461.	1.4	0
377	18f-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) for Assessment of Bone Marrow Metabolism in Patients with Myelofibrosis. <i>Blood</i> , 2014, 124, 1866-1866.	1.4	0
378	Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning, a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2014, 124, 1216-1216.	1.4	0

#	ARTICLE	IF	CITATIONS
379	Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. <i>Leukemia</i> , 2013, 27, 604-609.	7.2	105
380	Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2013, 48, 1395-1400.	2.4	37
381	Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous/Allogeneic Tandem Transplantation in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 398-404.	2.0	85
382	Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change. <i>Journal of Clinical Oncology</i> , 2013, 31, 3259-3271.	1.6	137
383	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013, 122, 1395-1398.	1.4	286
384	Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. <i>Leukemia</i> , 2013, 27, 1910-1913.	7.2	78
385	Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. <i>Experimental Hematology</i> , 2013, 41, 134-142.e3.	0.4	83
386	Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. <i>Annals of Hematology</i> , 2013, 92, 487-496.	1.8	35
387	Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. <i>Leukemia</i> , 2013, 27, 1229-1235.	7.2	195
388	Cytogenetics of extramedullary manifestations in multiple myeloma. <i>British Journal of Haematology</i> , 2013, 161, 87-94.	2.5	81
389	Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. <i>Bone Marrow Transplantation</i> , 2013, 48, 403-407.	2.4	45
390	The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2533-2542.	3.3	21
391	SETBP1 mutation analysis in 944 patients with MDS and AML. <i>Leukemia</i> , 2013, 27, 2072-2075.	7.2	60
392	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. <i>Blood</i> , 2013, 121, 5055-5063.	1.4	171
393	CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2013, 122, 3359-3364.	1.4	202
394	Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data. <i>PLoS ONE</i> , 2013, 8, e74368.	2.5	25
395	Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT. <i>Blood</i> , 2013, 122, 2092-2092.	1.4	0
396	Impact Of Conditioning Regimen, Donor Source, and DIPSS Score On Outcome Of Allogeneic Hematopoietic Stem Cell Transplantation For Myelofibrosis. <i>Blood</i> , 2013, 122, 712-712.	1.4	0

#	ARTICLE	IF	CITATIONS
397	Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. <i>Annals of Oncology</i> , 2012, 23, 2695-2703.	1.2	62
398	Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. <i>British Journal of Haematology</i> , 2012, 159, 172-181.	2.5	52
399	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
400	Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1035-1044.	10.7	237
401	Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. <i>Blood</i> , 2012, 119, 1599-1606.	1.4	254
402	Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. <i>Blood</i> , 2012, 119, 5632-5639.	1.4	67
403	Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. <i>British Journal of Haematology</i> , 2012, 157, 75-85.	2.5	88
404	Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma. <i>Anticancer Research</i> , 2012, 32, 2031-4.	1.1	18
405	National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 443-454.	2.0	39
406	Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. <i>Haematologica</i> , 2011, 96, 291-297.	3.5	51
407	Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. <i>Leukemia</i> , 2011, 25, 75-81.	7.2	47
408	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011, 29, 761-770.	1.6	724
409	Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. <i>Leukemia</i> , 2011, 25, 1657-1661.	7.2	30
410	Unrelated stem cell transplantation for patients with multiple myeloma. <i>Current Opinion in Hematology</i> , 2010, 17, 538-543.	2.5	7
411	Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 53-61.	2.3	11
412	Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma. <i>Cancer</i> , 2010, 116, 3621-3630.	4.1	44
413	Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2010, 148, 323-331.	2.5	55
414	Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning. <i>Journal of Clinical Oncology</i> , 2010, 28, 3344-3351.	1.6	83



#	ARTICLE	IF	CITATIONS
415	Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 405-411.	1.6	285
416	Outcome of Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 358-367.	2.0	245
417	Introduction to the Reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 563-564.	2.0	22
418	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1187-1211.	2.0	76
419	International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4521-4530.	1.6	156
420	Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. <i>Bone Marrow Transplantation</i> , 2010, 45, 1404-1407.	2.4	42
421	Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. <i>Blood</i> , 2010, 116, 3572-3581.	1.4	107
422	Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 1343-1352.	7.0	70
423	Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. <i>Experimental Hematology</i> , 2009, 37, 135-142.	0.4	66
424	Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. <i>Experimental Hematology</i> , 2009, 37, 791-798.	0.4	90
425	Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma. <i>Annals of Hematology</i> , 2009, 88, 401-404.	1.8	8
426	A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. <i>Bone Marrow Transplantation</i> , 2009, 44, 317-320.	2.4	49
427	HLA-Mismatched Unrelated Donors as an Alternative Graft Source for Allogeneic Stem Cell Transplantation after Antithymocyte Globulin-Containing Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 454-462.	2.0	38
428	Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. <i>Haematologica</i> , 2009, 94, 542-549.	3.5	108
429	JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. <i>Blood</i> , 2009, 113, 1866-1868.	1.4	88
430	Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2009, 114, 5264-5270.	1.4	366
431	Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. <i>Leukemia</i> , 2008, 22, 1961-1963.	7.2	18
432	Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. <i>Leukemia</i> , 2008, 22, 1250-1255.	7.2	79

#	ARTICLE	IF	CITATIONS
433	Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. <i>Experimental Hematology</i> , 2008, 36, 1047-1054.	0.4	41
434	Comparison of Two Doses of Antithymocyte Globulin in Patients Undergoing Matched Unrelated Donor Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 913-919.	2.0	67
435	Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1217-1225.	2.0	126
436	Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. <i>Haematologica</i> , 2008, 93, 1343-1350.	3.5	18
437	Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. <i>Blood</i> , 2007, 109, 1103-1112.	1.4	154
438	Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. <i>Blood</i> , 2007, 109, 1316-1321.	1.4	157
439	Miniâ€œMidiâ€œMaxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation. <i>Leukemia</i> , 2007, 21, 1851-1858.	7.2	25
440	Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. <i>Experimental Hematology</i> , 2007, 35, 1719-1722.	0.4	55
441	CD34+-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation. <i>Cytotherapy</i> , 2006, 8, 375-380.	0.7	15
442	Low Number of Donor Activating Killer Immunoglobulin-Like Receptors (KIR) Genes but not KIR-Ligand Mismatch Prevents Relapse and Improves Disease-Free Survival in Leukemia Patients After In Vivo T-Cell Depleted Unrelated Stem Cell Transplantation. <i>Transplantation</i> , 2006, 82, 1024-1030.	1.0	95
443	Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. <i>Bone Marrow Transplantation</i> , 2006, 37, 45-50.	2.4	71
444	Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). <i>Bone Marrow Transplantation</i> , 2006, 37, 339-344.	2.4	88
445	Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2006, 37, 1135-1141.	2.4	98
446	Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. <i>Experimental Hematology</i> , 2006, 34, 688-694.	0.4	44
447	Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. <i>Experimental Hematology</i> , 2006, 34, 770-775.	0.4	66
448	Antithymocyte Globulin Induces Ex Vivo and In Vivo Depletion of Myeloid and Plasmacytoid Dendritic Cells. <i>Transplantation</i> , 2005, 79, 369-371.	1.0	37
449	Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. <i>British Journal of Haematology</i> , 2005, 128, 690-697.	2.5	125
450	Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2005, 129, 631-643.	2.5	109

#	ARTICLE	IF	CITATIONS
451	Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. <i>Experimental Hematology</i> , 2005, 33, 1531-1536.	0.4	38
452	Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. <i>Leukemia</i> , 2004, 18, 659-662.	7.2	50
453	Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 698-708.	2.0	103
454	Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. <i>Blood</i> , 2004, 104, 3361-3363.	1.4	106
455	Impact of deletion 13q14 detected by fluorescence in situ hybridization on outcome after dose-reduced allogeneic stem transplantation in patients with multiple myeloma. <i>Journal of Clinical Oncology</i> , 2004, 22, 6536-6536.	1.6	0
456	Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM). <i>Bone Marrow Transplantation</i> , 2003, 31, 973-979.	2.4	38
457	Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. <i>Bone Marrow Transplantation</i> , 2003, 32, 1153-1157.	2.4	44
458	Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 2747-2753.	1.6	238
459	In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. <i>Bone Marrow Transplantation</i> , 2002, 29, 683-689.	2.4	58
460	Stem cell mobilisation with 16 µg/kg vs 10 µg/kg of G-CSF for allogeneic transplantation in healthy donors. <i>Bone Marrow Transplantation</i> , 2002, 29, 727-730.	2.4	50
461	Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , 2002, 118, 67-73.	2.5	95
462	Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. <i>British Journal of Haematology</i> , 2001, 112, 421-423.	2.5	45
463	Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with a. <i>British Journal of Haematology</i> , 2001, 113, 1060-1071.	2.5	75
464	Real-Time Quantitative Y Chromosome-Specific PCR (QYCS-PCR) for Monitoring Hematopoietic Chimerism after Sex-Mismatched Allogeneic Stem Cell Transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 419-425.	1.8	79
465	A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. <i>British Journal of Haematology</i> , 2000, 111, 761-5.	2.5	60
466	Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 × 5 µg/kg) compared to a single dose (1 × 10 µg/kg). <i>Bone Marrow Transplantation</i> , 1999, 23, 125-129.	2.4	30
467	The number of stem cell transplantations during the COVID-19 pandemic. <i>Deutsches Arzteblatt International</i> , 0, , .	0.9	0